Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: A 12-month randomized trial

Archives of Ophthalmology

Volumn 124, Issue 9, 2006, Pages 1230-1238

  Sherwood, Mark B ^a   Craven, E Randy ^b   Chou, Connie ^c   DuBiner, Harvey B ^d   Batoosingh, Amy L ^c   Schiffman, Rhett M ^c   Whitcup, Scott M ^c  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b Glaucoma Consultants of Colorado   (United States)

^c ALLERGAN INC   (United States)

^d Clayton Eye Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRIMONIDINE; BRIMONIDINE PLUS TIMOLOL; COMBIGAN; TIMOLOL; UNCLASSIFIED DRUG;

ADULT; AGED; ALLERGIC CONJUNCTIVITIS; ARTICLE; BLEPHAROCONJUNCTIVITIS; CHEMICAL CONJUNCTIVITIS; CHEMOSIS; CLINICAL TRIAL; CONJUNCTIVAL HYPEREMIA; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EMPHYSEMA; EYE ALLERGY; EYE INFLAMMATION; FEMALE; FOLLICULITIS; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORBIDITY; MULTICENTER STUDY; NAUSEA; OCULAR PRURITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY DISTRESS; SIDE EFFECT; SWEATING; TACHYCARDIA; TREATMENT OUTCOME; TREATMENT WITHDRAWAL;

ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OCULAR HYPERTENSION; OPHTHALMIC SOLUTIONS; PROSPECTIVE STUDIES; QUINOXALINES; TIMOLOL; TONOMETRY, OCULAR; TREATMENT OUTCOME;

EID: 33748596339     PISSN: 00039950     EISSN: 00039950     Source Type: Journal    
DOI: 10.1001/archopht.124.9.1230     Document Type: Article

References (25)

1. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701-713.
2. Collaborative Normal-Tension Glaucoma Study Group (CNTG). Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures [published correction appears in Am J Ophthalmol. 1999;127:120]. Am J Ophthalmol. 1998;126:487-497.
3. AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS), 7: the relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000;130:429-440.
4. Heijl A, Leske C, Bengtsson B, Hyman L, Bengtsson B, Hussein M; Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120:1268-1279.
5. Noecker RS, Dirks MS, Choplin NT, Bernstein P, Batoosingh AL, Whitcup SM. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol. 2003;135:55-63.
6. Parrish RK, Palmberg P, Sheu WP; XLT Study Group. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol. 2003;135:688-703.
7. Lichter PR, Musch DC, Gillespie BW, et al; CIGTS Study Group. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology. 2001;108:1943-1953.
8. Neufeld AH, Bartels SP, Liu JH. Laboratory and clinical studies on the mechanism of action of timolol. Surv Ophthalmol. 1983;28(suppl):286-292.
9. Toris CB, Camras CB, Yablonski ME. Acute versus chronic effects of brimonidine on aqueous humor dynamics in ocular hypertensive patients. Am J Ophthalmol. 1999;128:8-14.
10. Netland PA, Mroz M, Rosner SA, Katzman B, Macy JI. Brimonidine Purite and bimatoprost compared with timolol and latanoprost in patients with glaucoma and ocular hypertension. Adv Ther. 2003;20:20-30.
11. Zabriskie N, Netland PA; Brimonidine With Latanoprost Study Groups 1 and 2. Comparison of brimonidine/latanoprost and timolol/dorzolamide: two randomized, double-masked, parallel clinical trials. Adv Ther. 2003;20:92-100.
12. Day DG, Schacknow PN, Wand M, et al. Timolol 0.5%/dorzolamide 2% fixed combination vs timolol maleate 0.5% and unoprostone 0.15% given twice daily to patients with primary open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2003;135:138-143.
13. Simmons ST, Earl ML; Alphagan/Xalatan Study Group. Three-month comparison of brimonidine and latanoprost as adjunctive therapy in glaucoma and ocular hypertension patients uncontrolled on β-blockers. Ophthalmology. 2002;109:307-315.
14. Sall KN, Greff LJ, Johnson-Pratt LR, et al. Dorzolamide/timolol combination versus concomitant administration of brimonidine and timolol. Ophthalmology. 2003;110:615-624.
15. Arici MK, Sayici M, Toker M, Erdogan H, Topalkara A. A short term study of the additive effect of timolol and brimonidine on intraocular pressure. Eye. 2002;16:39-43.
16. Larsson LI. Aqueous humor flow in normal human eyes treated with brimonidine and timolol, alone and in combination. Arch Ophthalmol. 2001;119:492-495.
17. Lee DA, Gornbein JA. Effectiveness and safety of brimonidine as adjunctive therapy for patients with elevated intraocular pressure in a large, open-label community trial. J Glaucoma. 2001;10:220-226.
18. Yuksel N, Altintas O, Karabas L, Alp B, Caglar Y. The short-term effect of adding brimonidine 0.2% to timolol treatment in patients with open-angle glaucoma. Ophthalmologica. 1999;213:228-233.
19. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR; VEGF Inhibition. Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351:2805-2816.
20. American Academy of Ophthalmology. Preferred Practice Patterns: Primary Open-Angle Glaucoma. San Francisco, Calif: American Academy of Ophthalmology; 2000.
21. Melamed S, David R; Brimonidine Study Group II. Ongoing clinical assessment of the safety profile and efficacy of brimonidine compared with timolol: year-three results. Clin Ther. 2000;22:103-111.
22. Schuman JS, Horwitz B, Choplin NT, David R, Albracht D, Chen K; Chronic Brimonidine Study Group. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension: a controlled, randomized, multicenter clinical trial. Arch Ophthalmol. 1997;115:847-852.
23. Higginbotham EJ, Feldman R, Stiles M, Dubiner H; Fixed Combination Investigative Group. Latanoprost and timolol combination therapy vs monotherapy: one-year randomized trial. Arch Ophthalmol. 2002;120:915-922.
24. Noecker R. Effects of common ophthalmic preservatives on ocular health. Adv Ther. 2001;18:205-215.
25. Choudhri S, Wand M, Shields MB. A comparison of dorzolamide-timolol combination versus the concomitant drugs. Am J Ophthalmol. 2000;130:832-833.